{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    10,
    12,
    16,
    21,
    31,
    36,
    41,
    45,
    48
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_4",
        "affectedSection": "Section 3.5, 5.3.1.1, 5.4.1, 5.7, 6.1.6, 9.2, 9.3",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added benefits/risks evaluation and updated study procedures regarding the COVID-19 pandemic."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_4",
        "affectedSection": "Section 5.1, 5.3.1.1, Appendix F",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Introduced off-site phone visit options for subjects on stable single-agent therapy."
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_4",
        "affectedSection": "Section 5.3.1.1",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Modified tumor assessment schedule and central review requirements."
      },
      {
        "id": "impact_4",
        "amendmentId": "amend_4",
        "affectedSection": "Section 5.3.5, 8.1.8",
        "impactLevel": "Administrative",
        "instanceType": "StudyAmendmentImpact",
        "description": "Discontinued IDMC reviews following primary analysis."
      },
      {
        "id": "impact_5",
        "amendmentId": "amend_4",
        "affectedSection": "Section 5.3.3, 8.1",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Reclassified Duration of Response (DOR) from secondary to tertiary endpoint."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_4",
        "reasonText": "To address the ongoing COVID-19 pandemic and allow for procedure modifications like local labs and drug shipment.",
        "category": "Operational",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_4",
        "reasonText": "To add flexibility for subjects on study long-term while maintaining safety monitoring.",
        "category": "Operational",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "amend_4",
        "reasonText": "Sponsor was unblinded at the time of primary analysis (03 June 2019).",
        "category": "Administrative",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_4",
        "amendmentId": "amend_4",
        "reasonText": "To follow standard of care for patients with disease control and limit cumulative radiation exposure.",
        "category": "Scientific",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_5",
        "amendmentId": "amend_4",
        "reasonText": "To clarify the time period of reporting for specific adverse events of special interest with delayed onset.",
        "category": "Safety",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_4",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "5.3.1.1",
        "beforeText": "every 9 weeks from C1D-2",
        "afterText": "every 12 weeks from last scan (not to exceed 24 weeks per investigator discretion)",
        "summary": "Updated tumor assessment schedule interval for subjects with durable disease control."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_4",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "5.3.3",
        "beforeText": "secondary endpoint",
        "afterText": "tertiary endpoint",
        "summary": "Changed Duration of Response (DOR) endpoint classification to align with Statistical Analysis Plan."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_4",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "6.1.5",
        "afterText": "reporting of myelodysplastic syndrome, acute myeloid leukemia, or any secondary primary malignancy",
        "summary": "Added specific reporting requirements for AESIs with potential delayed onset."
      },
      {
        "id": "change_4",
        "amendmentId": "amend_4",
        "changeType": "Deletion",
        "instanceType": "StudyChange",
        "sectionNumber": "Global",
        "beforeText": "Blinded/Unblinded TA MD and study teams",
        "summary": "Removed references to separate blinded/unblinded sponsor teams following primary analysis unblinding."
      },
      {
        "id": "change_5",
        "amendmentId": "amend_4",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "8.1.3",
        "afterText": "additional OS analyses before the final OS analysis, if needed",
        "summary": "Clarified timing and conduct of additional interim survival analyses if requested by regulatory agencies."
      }
    ],
    "summary": {
      "impactCount": 5,
      "reasonCount": 5,
      "changeCount": 5
    }
  }
}